mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Bone marrow angiogenesis is a constant hallmark of multiple myeloma (MM) progression. 1 Plasma cells are seen as primary inducers of this process because they secrete major angiogenic factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor-2 and matrix metalloproteinases. Stromal cells behave as secondary inducers following recruitment and activation by plasma cells. 2 In particular, bone marrow endothelial cells from patients with multiple myeloma (MMEC) were shown to actively contribute to their own expansion and angiogenesis through an autocrine loop of growth in which VEGF is highly coexpressed with its cognate receptors. 3 The aim of the present study was to further investigate the vasculogenic potential of bone marrow multiple myeloma macrophages (MMMA) of patients with MM by testing them in vitro in the Matrigel assay and by using quantitative, morphometric methods to compare the patterns they formed with those generated by their endothelial counterpart. Moreover, a mathematical model of the self-assembly of the cells was elaborated to characterize the relationship between a set of cellular and biochemical parameters and the structure of the patterns formed by MMMA in vitro.
When seeded on Matrigel, a number of MMMA rapidly changed their morphology and developed an elongated shape. These cells appeared either as single cells or in clusters with round cells centrally and sprouts of elongated cells at the periphery. After 18 h, the formation of a pattern consisting of cord-and tubular-like structures was observed, sometimes arranged to form closed meshes. As detailed in Table 1 , the MMMA self-organization, resembling the first stages of vasculogenesis, was significantly less complex than the organization exhibited by their endothelial counterpart. The percent of area covered by the pattern was about half of that observed in endothelial cell cultures, with a lower number of meshes (2.170.6 per mm 2 ) and of branching points (5678 per mm 2 ). Figure 1 shows the results of the simulations performed by running the computational model of in vitro angiogenesis with different amounts of differentiated MA in the system. As outlined before, the biophysical parameters assumed in the simulations were consistent with the available experimental evidence. As illustrated, a good similarity between simulated and observed patterns was obtained when the percentage of differentiated MA in the system ranged from about 20 to 45%, with the best match (identified by the minimum value of the multivariate Mahalanobis distance) corresponding to a percentage of about 30%.
The results of the present study confirm that MMMA are able to form capillary-like structures when tested in the Matrigel assay, indicating that they can contribute to generate the vascular tree in the bone marrow of patients with MM through vasculogenesis. A quantitative, morphometric assessment of their angiogenic potential was also provided. Results have shown that MMMA self-organization, resembling the first stages of vasculogenesis, was significantly less complex than the organization exhibited by their endothelial counterpart, as indicated by the lower values obtained in all the parameters used to characterize the morphology of the pattern formed by the cells in vitro. When compared to the phenomenology observed with MA from normal tissues, however, the angiogenic process induced by MMMA appears quite fast, cord-and tubular-like structures being already formed after 18 h of culture on Matrigel.
The self-organization of the cells when seeded on Matrigel in vitro is the result of a number of intimately linked cell behaviours. Mathematical modelling provides a tool by which we may have an integrated view of the essential mechanisms leading to the self-assembly of the cells and of their relative effect. Several models have generated static patterns resembling those observed in vitro. [4] [5] [6] Of particular interest is a cellcentred 7 computational model of in vitro angiogenesis recently proposed by Merks et al., 8 since it was able to describe the time course of the in vitro angiogenesis generated by umbelical vein endothelial cells (HUVEC) cultured on Matrigel in good agreement with the experimental observations. The authors identified a minimal set of single-cell behaviours, including cell adhesion, chemotaxis and cytoskeleton rearrangement, which sufficed to quantitatively reproduce in vitro vascular formation and subsequent remodelling by HUVEC. In the present study, the same approach was followed and computer simulations based on that model were performed to study the relationships between cellular and biochemical parameters and the structure of the cell patterns observed in the different experimental conditions applied. When the input parameters of the model (chemoattractant type, chemoattractant release rate, cell size and elongation, chemotactic strength) were defined consistently with the available experimental data, the model that resulted was quite accurate in reproducing the self-assembly of cultured MMEC, confirming that cell elongation, in conjunction with autocrine secretion of a chemoattractant, results in a cell-shapedependent motility 8 representing the key factor driving the formation of vascular-like morphologies by endothelial cells in vitro. As far as MA are concerned, cell differentiation has to be added in order to reproduce the observed self-assembly of the cells. It involves a subset of the whole population, which under angiogenic stimulation develops an endothelial-like phenotype with the expression of specific surface markers. In the computational framework used in the present study to model the system, cell differentiation can be introduced in several ways. Methodologies inspired from the genetic regulatory network were proposed. Alternative methods simply use preprogrammed changes of the cells. In the present study, this second strategy was applied and a variable fraction of cells was allowed to assume in a quite short time a set of parameters close to the one used to model the MMEC. A good similarity between the patterns observed after 18 h in culture and the patterns generated by the model was obtained when the percentage of MA in the system able to differentiate towards an endothelial phenotype ranged from about 20 to 45%, with the best match corresponding to a percentage of about 30%. Such a model-derived prediction, although quite close to some experimentally obtained data from human peripheral blood monocytes, would need further specific experiments on MMMA to be fully confirmed. Nevertheless, it suggests that a quite high number of MMMA could become involved in the process of capillarization by converting into a cell type at least similar to the endothelial one, with the potential to rapidly form new vessels. This may open up new windows for therapeutic management in patients with MM. Abbreviation: MM, multiple myeloma.
Figure 1
Typical patterns obtained from the simulation model of MMMA in vitro organization with increasing percentages of differentiated cells in the system. Each simulated pattern underwent the same morphometric analysis performed on real samples. Thus, it was characterized with a set of five parameters (area%, length, number of meshes, number of branching points and fractal dimension). The multivariate distance (according to Mahalanobis) between this set of values and the set of values measured on real samples was used as an estimate of the similarity between the simulated patterns and the experimental ones. In the figure, such a distance is plotted as a function of the assumed percentage of differentiated MMMA in the cell population. The dotted line indicates the 95% confidence limit around the 0 value of the distance. The highest similarity with the experimental patterns (that is, the minimum distance) was found to correspond to a percentage of about 30%.
Letters to the Editor
Actuarial long-term disease-free survival (DFS) for adults with acute lymphoblastic leukemia (ALL) less than 60 years of age is 29-39% in large multicentre studies. [1] [2] [3] [4] We have previously reported favorable outcome for patients less than 60 years of age treated according to our institutional protocol: actuarial 8-year overall survival (OS) 47% and DFS 44%. 5 Actual survival, however, is rarely reported in the medical literature. The purpose of this report is to present the actual 8-year survival for adults with ALL treated in our hospital.
Induction therapy included prednisone, vincristine, L-asparaginase, doxorubicin and cyclophosphamide. Consolidation was daunorubicin, cytarabine and 6-thioguanine, followed by two courses of high-dose methotrexate and 6-mercaptopurine orally for 7 weeks. Maintenance was prednisone, vincristine, doxorubicin and cyclophosphamide followed by methotrexate alternating with 6-mercaptopurine orally as part of 12-week re-induction cycles for 3 years. Central nervous system prophylaxis consisted of 10 intrathecal injections of methotrexate. The protocol has been described in detail elsewhere. 5 Highdose methotrexate was increased from 500 to 1500 mg/m 2 through 1000 mg/m 2 following our previous report, but apart from this dose escalation the protocol has been unchanged during the study period. Patients in 2.complete remission (2.CR) with a suitable donor were allografted as part of salvage therapy. From the early 1990s, patients with high-risk ALL (t(9;22), 11q23 abnormalities, complex karyotype, pro-B or pro-T immunophenotype) were allografted in 1.complete remission (1.CR), if a suitable donor was available.
Between October 1982 and December 1998, 105 patients, aged 15-59 years, received treatment for ALL with a curative intention in our hospital (Table 1) . Patients were followed to death or for a minimum of 96 months. Eight patients died during induction therapy, leaving behind 97 patients eligible for response evaluation. CR was accomplished in 94 patients (94/105 patients; 90%). Three patients had therapy-refractory leukemia and died from progressive disease. Five patients with high-risk ALL were allografted in 1.CR, and 89 patients were offered chemotherapy alone as their first-line therapy. Actual 8-year OS and DFS were 50% (53/105 patients) and 50% (52/ 105 patients), respectively. Following chemotherapy alone, 49 patients (47% of the total cohort and 51% of those achieving remission) were alive in remission at 8 years. However, very late relapses do occur. One patient relapsed at 135 months, and died during allografting in 2.CR. Of 94 patients 37, (39%) have relapsed following first-line therapy; 35 of 89 patients relapsed following chemotherapy and 2 of 5 patients following an allograft in 1.CR. After achieving 1.CR, 41 patients have died: 35 due to relapse and 6 in remission (3 during maintenance chemotherapy, 1 from a second malignancy and 2 within the first months of an allograft). Allografting in 2.CR was performed in 12 patients. Two patients enjoy a sustained remission, six have died from relapse, three died from transplant-related mortality and one is alive with relapse 8 years after allografting. 
